Skip to main content
Publications
Trickey A, Nixon E, Christensen H, Finn A, Thomas A, Relton C, Montgomery C, Hemani G, Metz J, Walker JG, Turner K, Kwiatkowska R, Sauchelli S , Danon L, Brooks-Pollock E. University students and staff able to maintain low daily contact numbers during various COVID-19 guideline periods . Epidemiol Infect. 2021 Aug 10;149:e169. doi: 10.1017/S0950268821001618
Horn L, Bauml J, Forde PM, Davis KL , Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer . Lung Cancer. 2019 Feb;128(2019):74-90. doi: 10.1016/j.lungcan.2018.12.003
Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C , Hollis K , Sweeney C , Price M , Wolowacz S , Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS) . Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007
Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M , Chirila C , Hollis K , Sweeney C , Wolowacz S , Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study . Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.
MacDougall JE, Johnston JM, Lavins BJ, Nelson LM , Williams VS , Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials . Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089